FDA Brief

Warning letters Drugs

FDA warning letter to

globalpharmacyplus.com

High riskIssued Dec 27, 2022Posted Jan 3, 2023

FDA warned globalpharmacyplus.com in Canada for selling unapproved and misbranded prescription drugs to U.S. consumers online.

What happened

FDA reviewed the website www.globalpharmacyplus.com and found it offered prescription drugs for sale to U.S. consumers without FDA-approved applications and with labeling that lacked adequate directions and warnings. The examples cited were Molnunat 200 (molnupiravir) for COVID-19 and transplant drugs CellCept 500mg (mycophenolate mofetil) and Tacrolimus Capsules Tacrograf – 0.5.

What FDA found

  1. The website offered unapproved new drugs for sale to U.S. consumers without FDA-approved applications.

    FD&C Act sections 301(d) and 505(a) [21 U.S.C. §§ 331(d), 355(a)]
  2. The website offered molnupiravir as Molnunat 200 with claims to treat COVID-19, but FDA had not approved or authorized that product.

    FD&C Act sections 301(d) and 505(a) [21 U.S.C. §§ 331(d), 355(a)]
  3. The website offered mycophenolate mofetil as CellCept 500mg without an FDA-approved application, while FDA-approved versions have a REMS (a drug safety program) and a boxed warning (FDA’s strongest warning).

    FD&C Act sections 301(d) and 505(a) [21 U.S.C. §§ 331(d), 355(a)]
  4. The website offered tacrolimus as Tacrolimus Capsules Tacrograf – 0.5 without an FDA-approved application, and oral tacrolimus is a narrow therapeutic index drug (small dose differences can be dangerous).

    FD&C Act sections 301(d) and 505(a) [21 U.S.C. §§ 331(d), 355(a)]
  5. The prescription drugs’ labeling lacked adequate directions for use by a layperson, making them misbranded.

    FD&C Act section 502(f)(1) [21 U.S.C. § 352(f)(1)]; section 301(a) [21 U.S.C. § 331(a)]
  6. The drugs’ labeling lacked adequate warnings, including for mycophenolate, so important safety measures for FDA-approved versions could be bypassed.

    FD&C Act section 502(f)(2) [21 U.S.C. § 352(f)(2)]

What FDA wants

FDA asks the company to stop offering any unapproved or misbranded drugs for sale to U.S. consumers and to respond in writing within 15 working days with the steps taken to correct the violations and prevent recurrence.

Who should pay attention

  • online pharmacies that ship to U.S. patients
  • sellers of COVID-19 treatment products
  • transplant drug suppliers and pharmacists

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Phuoc Loc Tho Herbals, Inc.

    FDA warned Phuoc Loc Tho Herbals that its herbal products are unapproved new drugs marketed with disease claims.

    High risk
  4. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk